PTC Therapeutics (PTCT) and The Competition Critical Contrast

PTC Therapeutics (NASDAQ: PTCT) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare PTC Therapeutics to related companies based on the strength of its risk, earnings, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares PTC Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PTC Therapeutics -75.64% -75.19% -31.76%
PTC Therapeutics Competitors -5,338.36% -435.70% -40.49%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for PTC Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PTC Therapeutics 1 6 2 0 2.11
PTC Therapeutics Competitors 843 3191 11570 230 2.71

PTC Therapeutics presently has a consensus target price of $18.14, suggesting a potential upside of 15.05%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.57%. Given PTC Therapeutics’ competitors stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares PTC Therapeutics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
PTC Therapeutics $82.71 million -$142.11 million -5.46
PTC Therapeutics Competitors $284.30 million $34.29 million 137.48

PTC Therapeutics’ competitors have higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

86.2% of PTC Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.1% of PTC Therapeutics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

PTC Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, PTC Therapeutics’ competitors have a beta of 6.10, meaning that their average share price is 510% more volatile than the S&P 500.

Summary

PTC Therapeutics competitors beat PTC Therapeutics on 8 of the 12 factors compared.

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply